//• 2025 ASH年会上,CAR-T治疗多发性骨髓瘤研究的摘要有140多个;• 体内CAR-T疗法在复发难治性多发性骨髓瘤患者中MRD阴性率100%,三个月内均保持MRD阴性反应,5个月随访期内所有患者均保持应答状态;• 科济、瓴路、驯鹿这些中国本土CAR-T公司的产品也崭露头角。总体缓解率(ORR)达100%,严格完全缓解率(sCR)达到97%,单次输注的中位无疾病进展生存期(mPFS)...
Source Link//• 2025 ASH年会上,CAR-T治疗多发性骨髓瘤研究的摘要有140多个;• 体内CAR-T疗法在复发难治性多发性骨髓瘤患者中MRD阴性率100%,三个月内均保持MRD阴性反应,5个月随访期内所有患者均保持应答状态;• 科济、瓴路、驯鹿这些中国本土CAR-T公司的产品也崭露头角。总体缓解率(ORR)达100%,严格完全缓解率(sCR)达到97%,单次输注的中位无疾病进展生存期(mPFS)...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.